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Abstract 
Vascular disruption is one of the pathological hallmarks in acute respiratory distress 
syndrome (ARDS). Bone marrow (BM)-derived circulating endothelial progenitor cells 
(EPCs) and lung tissue-resident EPCs have been considered to play a pivotal role in 
pulmonary vascular repair; however, which population is predominant in local 
pulmonary vasculogenesis remains to be clarified. We therefore examined the origin 
of EPCs participating in the regenerative process of pulmonary vascular endothelial 
cells (PVECs) in experimental ARDS. Lung samples from mice administered LPS 
intratracheally were investigated for cell dynamics and EPC functions. Quantitative 
flow cytometric analysis demonstrated that the number of PVECs decreased by ~20% 
on day 1, and then recovered on day 7 of LPS challenge. Bromodeoxyuridine-
incorporation assays and immunofluorescence microscopy demonstrated that 
proliferating PVECs preferentially located in the capillary vessels. Experiments using 
BM chimera mice revealed that most of the regenerating PVECs were tissue-resident 
cells and BM-derived cells hardly engrafted as PVECs. The population of circulating 
putative phenotypical EPCs decreased during the first week after LPS challenge. The 
regenerating PVECs were characterized by high colony-forming and vasculogenic 
capacities, intracellular reactive-oxygen-species scavenging and aldehyde 
dehydrogenase activites, and enhanced gene expression of Abcb1b (a drug resistant 
gene), suggesting that the population of PVECs included tissue-resident EPCs 
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activated during regenerative process of PVECs. The proliferating PVECs expressed on 
the surface more strongly CD34, Flk-1/KDR and c-kit and less Prom1/CD133 than 
non-proliferating PVECs. Our findings indicated that lung tissue-resident EPCs 
predominantly contribute to pulmonary vascular repair after endotoxin-induced injury.  
 
Key words 
Acute respiratory distress syndrome, Endothelial progenitor cells, Vascular 
regeneration, Endothelial repair, Lipopolysaccharide 
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Introduction 
Acute respiratory distress syndrome (ARDS) is a severe intractable clinical condition 
with a high mortality rate in spite of intensive care. Destruction of pulmonary 
endothelium is one of the pathological hallmarks in the acute exudative phase of 
ARDS, accompanied by infiltration of inflammatory cells and epithelial injury (1, 2). 
Appropriate angiogenesis is necessary for tissue repair during ARDS and 
normalization of vascular permeability avoids influx of exudative fluid and 
inflammatory cells leading to amelioration of the disease (3).  
 
Endothelial progenitor cells (EPCs) probably participate in the repair of the vascular 
endothelium (4). Since the pioneering work by Asahara published in 1997 (5), 
accumulating evidence has demonstrated that adult mammals have circulating EPCs, 
which derive from bone marrow (BM) and migrate toward vascular lesions where they 
contribute to vasculogenesis (6-8). In contrast, tissue-resident EPCs derived from 
large vessels have recently been suggested as leading candidates for vascular repair 
in peripheral organs, because of their significant potential for cell proliferation, colony 
formation, drug excretion and vascular tube formation (9, 10).  
 
Meanwhile, circulating EPCs have also been shown to play a role in the restoration 
of injured pulmonary vessels in human and animal studies. The increased number of 
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circulating EPCs of ARDS patients (11, 12) and the corresponding animal model (13), 
and the therapeutic effect of transplantation of BM-derived circulating EPCs (14, 15) 
strongy suggest a restorative function of these cells. Yet, the ability of endogenous 
circulating EPCs to reside within the lung and replace the wounded vessels under 
physiological/pathophysiological conditions has been a matter of controversy (16-18). 
Furthermore, the existence of lung tissue-resident EPCs has been reported (19-21). 
But what role the EPCs play under physiological/pathophysiological conditions remains 
to be elucidated. 
 
In this study, we aimed to determine the origin of EPCs participating in the 
regeneration of pulmonary vascular endothelial cells (PVECs) with experimental 
ARDS. Because bacterial or viral pneumonia is the most common cause of ARDS (1), 
we used a mouse model of lung injury induced by intratracheal administration of LPS 
as the most suitable for mimicking human ARDS with good reproducibility (22), and a 
flow cytometric quantitative technique to evaluate the potential of lung vessels for 
undergoing endogenous regeneration. In addition, discrimination between circulating 
and tissue-resident EPCs was accomplished by BM reconstitution using fluorescent 
labeled cells, which allowed us to determine the active participants in pulmonary 
vascular repair. 
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Methods 
Additional details are provided as online data supplement. 
 
Endotoxin-induced lung injury 
Seven- to eight-week-old female C57BL/6 mice were intratracheally administered 100 
µg LPS derived from Escherichia coli (O55:B5) and dissolved in 100 µl PBS. All animal 
experiments were conducted under protocols approved by the Review Board for 
animal experiments of Chiba University.  
 
Flow cytometry (FCM) of lung cells 
Lung cells were pretreated with anti-CD16/32 antibody, and then incubated with the 
following reagents: anti-CD31, -CD45, -CD11b, -Ly-6G/Ly-6C (Gr-1), -Flk-1/KDR, -
CD34, -CD133/Prom1, and -CD117/c-kit antibodies, Hoechst 34580, 
dichlorofluorescein diacetate (DCF-DA), ALDEFLUORTM kit , Propidium iodide (PI) and 
bromodeoxyuridine (BrdU) APC flow kit. The Respective isotypes were used as 
negative controls. Multicolor analysis was performed on FACSCantoTM II (Becton 
Dickinson, San Jose, CA). 
 
Confocal microscopy analysis  
Lung cryosections were immunostained with anti-CD31, -Ki67, and -CD45 antibodies 
7 
 
and Hoechst 34580 and visualized using a confocal microscope (Fluoview FV 10i, 
Olympus, Tokyo, Japan). 
 
BM reconstitution 
Donor BM cells were obtained from transgenic (Tg) mice expressing enhanced green 
fluorescent protein (GFP) under CAG promoter (GFP-Tg mice). Recipient wild-type 
(WT) mice (5 weeks old) were irradiated with 9.5 Gy and then donor BM cells (1.0 × 
107 cells) were injected via the tail vein.  
 
BM intravenous transfusion experiment 
Non-irradiated WT mice were injected BM cells obtained from GFP-Tg mice (1.0 × 107 
cells) through the tail vein on days 3 and 6, and analyzed on days 7 and 21 of LPS 
challenge. 
 
Evaluation of dynamics of circulating phenotypical EPCs  
Mouse blood was withdrawn from the inferior vena cava and then red blood cells were 
lysed by adding 0.2% saline. The remaining cells were incubated first with anti-
CD16/32 antibody, and then with anti-Flk-1/KDR, -CD34, -CD133, -CD31 and -CD45 
antibodies. 
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Isolation of mouse PVECs  
CD31+/CD45- PVECs were isolated by magneto-beads method. 
 
Colony formation assay  
Primary PVECs (1.0 × 106 cells/well) were cultured on gelatinized 6-well plates. After 
12 days, the number of colonies consisting of 30 or more cells, was counted. 
 
Vasculogenesis assay in vitro 
Primary PVECs (4.0 × 105 cells/well) were cultured on MatrigelTM-coated chamber 
slides, and analyzed by microscopy. 
 
Vasculogenesis assay in vivo 
Primary PVECs were isolated from GFP-Tg mice on day 5 of LPS challenge (GFP-
PVECs) and then expanded. GFP-PVECs (1.0 × 105 cells: passage 6) mixed with 400 
µl of MatrigelTM supplemented with VEGF and bFGF were injected subcutaneously into 
the dorsal region of WT mice. After 10 days, the plugs were harvested and 
cryosections were immunostained with anti-CD31 and -GFP antibodies and Hoechst 
34580 to be analyzed using a confocal microscope. 
 
Quantitative polymerase chain reaction (PCR) analysis 
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Total RNA was isolated from primary PVECs, processed for quantitative reverse 
transcription PCR and then analyzed. 
 
Statistical analysis 
Values are showed as mean ± SD unless otherwise described, or median (25–75th 
percentile). Comparisons were performed using Student’s t test, one-way ANOVA or 
Kruskal-Wallis test followed by Tukey’s or Dunn’s multiple comparison as post hoc 
test. P < 0.05 was considered statistically significant using GraphPad PRISM software 
(Version 6.03; GraphPad Software, San Diego).  
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Results 
The number of PVECs decreased transiently after LPS challenge, followed by 
recovery on day 7.  
The changes in body weight and results of FCM analyses of lung cells after LPS 
challenge are shown in Figure 1. There was a significant loss of body weight until day 
3 (Figure 1A) and a marked mobilization of leukocytes defined as CD31-/CD45+ cells 
(Figure 1B) that comprised mainly neutrophils defined as Gr-1+/CD11b+/CD31-/CD45+ 
cells (Figure 1C). The number of PVECs defined as CD31+/CD45- cells decreased 
significantly on day 1 and 3 (median; 20.0 and 23.2% decrease), and then recovered 
on day 7 (Figure 1D). Hoechst dye staining revealed an increase of apoptotic PVECs 
with fragmented DNA on day 1 followed by a significant decrease on day 7 (Figure 
1E), and BrdU-incorporation assay showed a significant increase of BrdU+ proliferating 
PVECs on days 3, 5 and 7 (Figure 1F, G). The CD31+ cell purity of isolated PVECs were 
96.0 ± 1.0% in controls, 92.7 ± 4.0% on day 1, 91.6 ± 0.8% on day 3, 94.3 ± 2.2% 
on day 5 and 95.1 ± 2.2% on day 7; and quantitative PCR analyses of these PVECs 
showed a significant increase of Mki67, a marker of proliferation, expression on day 7 
(Figure 1H), supporting the result of BrdU-incorporation assay. Other representative 
panels of FCM analyses are shown in Figure E1.  
 
Proliferating PVECs preferentially located in capillary vessels rather than in 
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non-capillary vessels in the reparative phase of LPS-lung injury.  
We performed immunofluorescent analyses to determine the histological location of 
proliferating PVECs after LPS challenge (Figure 2). In the capillary vessel area (Figure 
2A), similar to control lung tissue, few proliferating PVECs defined as 
CD31+/Ki67+/CD45- cells were detected on day 1 of LPS-induced injury. The alveolar 
structure was destroyed and showed accumulation of CD31-/CD45+ leukocytes on day 
3. The excessive number of leukocytes mostly disappeared on days 5 and 7, and 
proliferating PVECs emerged as the restructure of alveolar epithelia on days 3, 5 and 
7. On the other hand, in non-capillary proximal vessels (Figure 2B), few proliferating 
PVECs were detected throughout the week.  
 
From the results of BW change, FCM and histological analyses of lung tissue, we 
defined days 5-7 of LPS challenge as the proliferation phase of PVECs and reparative 
phase of the endothelium and lung injury. Furthermore, we quantified the 
proliferating PVECs in lungs from controls and mice of day 5 after LPS challenge to 
clarify whether the number of PVECs depended on the anatomical location. To 
determine the location of proliferating PVECs, we separated vessels into three groups 
by diameter and morphology: 100 μm or more as “large”, 5 to 100 μm as “middle”, 
and less than 5 μm and flattened shape as “capillary” vessels. Then, the number of 
proliferating PVECs per 100 PVECs defined as CD31+/CD45- cells was compared. As 
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shown in Figure 2C, few proliferating PVECs were observed in large, middle (non-
capillary) and capillary vessels of control lungs. Whereas, the number of proliferating 
PVECs was significantly increased only in the capillary area, in tissue obtained in the 
reparative phase of lung injury.  
 
Most of new PVECs originated from non-BM-derived cells 
To determine the origin of new PVECs observed after LPS challenge, we used mice 
reconstituted with GFP-expressing BM cells to distinguish BM-derived (GFP+) from 
non-BM derived (GFP-) cells (Figure 3). More than 6 weeks after BM reconstitution, 
the percentage of GFP+ cells in peripheral blood cells, lung interstitial leukocytes and 
PVECs of the recipients (Figure 3A-C) were 94.1 ± 1.7% (n=35), 87.3 ± 1.5% (n=3), 
and 1.78 ± 0.4% (n=3), respectively. After administration of LPS to these mice, the 
percentage of GFP- in PVECs on days 0 (before LPS challenge), 7 and 21 of LPS 
challenge (Figure 3D, E) were 98.2 ± 0.6%, 97.3 ± 0.7% and 98.7 ± 0.7%, 
indicating GFP- PVECs continued to significantly predominate during long-term follow 
up after LPS challenge. The percentage of BrdU+ cells in PVECs (Figure 3F) was 
significantly increased on day 7 (8.9 ± 2.6%) similarly to the course observed in 
experiments with WT mice, and the percentage of GFP+ cells in BrdU+ PVECs (Figure 
3G) decreased after LPS challenge (days 0, 7 and 21; 5.5 ± 1.3%, 3.9 ± 0.7% and 
4.1 ± 0.1%). These results indicate most of the new PVECs originated from non-BM 
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derived cells. Representative panels of FCM analyses are shown in Figure E2. 
 
BM-derived cells hardly engrafted as PVECs  
Considering the possibility that the irradiation used in the BM reconstitution affected 
the engraftment of BM-derived cells as PVECs, we performed a BM intravenous 
transfusion experiment to determine whether BM-derived cells would engraft as 
PVECs and proliferate at the implantation site. After 3 and 6 days of LPS challenge, 
non-irradiated recipient WT mice were injected with GFP-expressing BM cells (1.0 × 
107 cells in 200 µl PBS) through the tail vein and the lungs were analyzed on days 7 
and 21 of LPS challenge. Recipient mice without LPS challenge were used as controls. 
In LPS challenged mice (Figure 3H, 3I), the number of GFP+ cells among leukocytes 
and PVECs clearly differed. In addition, significant increases in the number of GFP+ 
lung interstitial leukocytes (Figure 3H) were observed in the mice after LPS challenge 
compared to the controls (days 7 and 21; 109.3 ± 60.4% and 282.5 ± 300.1% 
higher than the controls). In contrast, the number of GFP+ PVECs in mice after LPS 
challenge (Figure 3I) was slightly lower than in the controls (days 7 and 21; 24.4 ± 
37.1% and 0.6 ± 11.5% lower than the controls), and tended to decrease from day 7 
to day 21. These findings supported the notion that BM-derived cells hardly engrafted 
as PVECs or proliferated during the reparative process of PVECs. Representative 
panels of FCM analyses are shown in Figure E3. 
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The population of circulating phenotypical EPCs decreased after LPS 
challenge 
As few BM derived cells were found to have engrafted as PVECs in controls and during 
repair of pulmonary vessels, we evaluated the dynamics of circulating putative 
phenotypical EPCs. Because different combinations were reported with regard to the 
EPC definition (23, 24), we applied two pairs of surface markers; i.e.Flk-1/KDR and 
CD133/Prom1, or Flk-1/KDR and CD34. In either case (Figure 4A, B), the number of 
circulating EPCs significantly decreased on day 1 and then gradually increased but 
remained below the basal level until day 7 of LPS challenge, suggesting that 
circulating phenotypical EPCs rarely participate in vascular repair in damaged lungs.  
 
Furthermore, considering that tissue-resident EPCs in other organs may mobilize into 
the circulation and be delivered to the injured lungs (9), we examined the number of 
circulating CD31+/CD45- cells, for these are considered to include tissue-resident 
EPCs (9, 19, 20). These cells increased slightly on day 1, but remained unchanged or 
below levels during the reparative phase (day 5-7) of the endothelium (Figure 4C), 
suggesting that although the population of injured PVECs transiently drop into the 
circulation, but tissue-resident EPCs are rarely supplied from other organs through 
the circulation during regenerative phase of PVECs. Representative panels of FCM 
15 
 
analyses are shown in Figure E4. 
 
Regenerating PVECs showed several characters of progenitor cells  
Because EPCs involved in pulmonary vascular repair are considered to be rarely 
supplied through the circulation, we speculated that most of the regenerating PVECs 
originated from lung tissue-resident EPCs and investigated whether tissue-resident 
PVECs included EPCs that were activated after the LPS challenge. 
 
Colony-forming and vasculogenic capacities in vitro 
Colony-formation capacity and vasculogenesis are considered as essential functions of 
EPCs (19-21); therefore, we at first performed colony-formation and vasculogenesis 
assays in vitro using PVECs isolated from the lungs of control mice (control-PVECs) 
and mice in the reparative phase of lung injury (day 5 of LPS challenge; LPS-PVECs). 
After isolation of PVECs, CD31+ cell purity in control- and LPS-PVECs was 97.5 ± 
0.2% and 95.0 ± 0.8%, and we started culturing these cells on gelatinized 6-well 
plates. Daily microscopic observation demonstrated (Figure 5A) that a part of PVECs 
adhered to the plate and began to proliferate within a couple of days, followed by 
distinct colony formation, which consisted of 30 or more, spindle-shaped and cobble 
stone-like cells, until day 12. The number of colonies formed by LPS-PVECs was 
significantly higher than that formed by control-PVECs on day 12 (Figure 5B). The 
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colonies consisted of CD31+ cell, their cell purity was 95.8 ± 5.6% (n = 8, passage 1-
9), and could be expanded over 20 passages.  
 
When vasculogenesis assay was performed on MatrigelTM-coated chamber slides, 
control- and LPS-PVECs began to form tiny sphere-like cell assemblies within 7 days, 
and then some of these colonies became gradually larger. The control-PVECs 
aggregates showed only short tube-like structures on day 15, but the structure did 
not expand until day 28 (Figure 5C). Conversely, the LPS-PVECs aggregates showed a 
large net-like structure around them on day 12, which seemed to be formed by the 
connection of thin-wall cellular tubes, and the structure expanded until day 15, 
whereas a part of the spheroids gradually shrank (Figure 5D). For comparison (Figure 
5E), endothelial cells isolated from the heart and aorta of WT normal mice (CD31+ cell 
purity were 92.6% and 40.2%) were seeded; these formed spheroids with a net-like 
structure the same as the PVECs did.  
 
Vasculogenic capacity of PVECs in vivo 
Vasculogenic capacity in vivo and in vitro is one of the fundamental properties of EPCs 
(19-21); therefore, we injected LPS-PVECs from GFP-Tg mice (GFP-PVECs; passage 6) 
together with 400ul MatrigelTM subcutaneously into the back of WT normal mice to 
confirm their vasculogenic capacity. After 10 days, we harvested the plugs and 
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analyzed them using a confocal microscope. We found vessel structures in the plugs 
(Figure 5F) and GFP-PVECs were integrated into the vessel-like structure (Figure 5G), 
suggesting proliferating PVECs hold a vasculogenic capacity in vivo as well. 
 
Intracellular reactive-oxygen-species scavenging activity 
Cellular resistance to oxidative stress is one of the functional features of 
stem/progenitor cells (25), therefore, we performed FCM analysis of intracellular 
reactive-oxygen-species (ROS) in PVECs using 2’, 7’-dichlorofluorescein diacetate 
(DCF-DA) as a ROS indicator to determine whether PVECs show a stem/progenitor 
function during the regenerative process. As a result (Figure 6A), we found that the 
fluorescence intensity of oxidized DCF-DA increased more than 50 % on day 1 and 
decreased significantly on day 7, indicating that PVECs contain a growing cell 
population that scavenges intracellular ROS. Furthermore, we quantitatively analyzed 
the expression of 6 genes associated with the ROS-scavenging function (26) of 
isolated PVECs. As a result (Figure 6B), we found that the expression of Cat, Gpx1 
and Sod2 increased after LPS challenge, supporting the result of FCM analysis. 
Representative panels of FCM analyses are shown in Figure E5. 
 
Aldehyde dehydrogenase activity  
Aldehyde dehydrogenase (ALDH) is highly expressed in various types of 
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stem/progenitor cells and has recently been recognized to be a functional marker of 
these cells (27). FCM analysis of PVECs revealed (Figure 6C) that 3.3 ± 0.8% of 
control PVECs expressed ALDH activity (ALDH+PVECs) and the percentage of 
ALDH+PVECs increased slightly after LPS challenge. In addition, we analyzed 3 genes 
related to ALDH activity (28). As a result (Figure 6D), we found the expression of 
Aldh1b1 and Aldh2 increased slightly in LPS-PVECs. Representative panel of FCM 
analyses are shown in Figure E6. 
 
Expression of drug resistance genes 
Since several ATP-binding cassette (Abc) transporter genes, which are associated with 
the efflux of noxious reagents from the cells, have been used as functional markers of 
stem/progenitor cells (29), we examined the expression of 4 Abc transporter genes: 
Abcb1a, Abcb1b, Abcg1 and Abcg2. The result showed all of these genes tended to 
increase, and in particular the expression of Abcb1b increased significantly during the 
regenerative process of PVECs (Figure 6E), reflecting the survival potential of PVECs 
after damage induced by LPS-challenge.  
 
Expression of putative EPC marker differed between proliferating PVECs and 
the rest of PVECs  
Regenerating PVECs showed activation of EPC-compatible functions, therefore, we 
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considered that tissue-resident PVECs contained EPCs activated by the LPS challenge. 
Lastly, we examined whether tissue-resident EPCs showed enhanced expression of 
putative EPC gene and cell surfaces: CD34, Flk-1/KDR, Prom1/CD133 and c-kit (5, 
19, 30). As a result (Figure 7A), gene expression of Cd34 in whole PVECs increased 
significantly on days 3 and 5, whereas that of Kdr, Prom1 and Kit were equal or below 
the control levels in LPS-PVECs, suggesting that Cd34 was particularly enhanced in 
regenerating PVECs. In addition, because it was indicated that most of the 
regenerating PVECs originated from lung tissue-resident EPCs, we regarded 
proliferating PVECs as lung tissue-resident EPCs. Then, we compared the expression 
of cell surface markers on non-proliferating (BrdU-) and proliferating (BrdU+) PVECs of 
day 7 after LPS challenge to confirm whether these markers could serve to 
discriminate the two population. The percentages of BrdU- and BrdU+PVECs were 86.3 
± 3.9 and 12.4 ± 3.4%. As a result (Figure 7B), the positive percentage of each 
marker in BrdU- or BrdU+PVECs was as follows: CD34, 42.7 ± 2.0 vs. 62.4 ± 1.7% (P 
<0.01); Flk-1/KDR, 1.9 ± 0.3 vs. 3.2 ± 0.3% (P <0.05); Prom1/CD133, 12.4 ± 1.5 
vs. 8.7 ± 1.5% (P <0.05); c-kit, 31.9 ± 2.9 vs.52.0 ± 4.1% (P <0.01), and we found 
that proliferating PVECs expressed significantly more strongly CD34, Flk-1/KDR and c-
kit, but significantly less Prom1/CD133 than non-proliferating PVECs. Representative 
panels of FCM analyses are shown in Figure E7. 
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Discussion 
We aimed to determine the origin of EPCs participating in the regenerative process of 
PVECs in experimental ARDS, and demonstrated that lung tissue-resident EPCs rather 
than circulating EPCs play a major role in pulmonary vascular repair of endotoxin-
induced injury. 
 
In this research, we focused on pulmonary vessel regeneration, which is a key 
determinant of overall lung regeneration (4) and quantitatively examined the change 
in the number of CD31+/CD45- PVECs using FCM. After challenge of LPS, about 20% 
of PVECs was lost in the early phase, but they recovered reaching the basal level 
within a week, none of the mice died and their general condition and inflammation 
improved, suggesting a strong regenerative potential of the lung. These highly 
reproducible data led us to wonder about the origin of regenerated PVECs and the 
possible contribution of an EPC subpopulation. In the field of EPC research, lack of 
unique cell markers for EPCs is a very critical issue (31). Consequently, in the present 
study, we regarded proliferating PVECs as EPCs, and examined the existence of 
circulating EPCs using different surface markers and whether properties like those of 
progenitor cells were activated during the reparative process of PVECs after LPS 
challenge. 
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 Regarding the origin of lung EPCs, we used BM-chimera mice to distinguish tissue-
resident from BM-derived circulating cells and set more than 2 month between BM 
transplantation and LPS challenge to mimic the physiological pulmonary circulatory 
condition. As a result, we established ~95% chimerism in peripheral blood cells, 
avoiding underestimation due to insufficient BM reconstitution and lung interstitial 
leukocytes were efficiently replaced by BM-derived cells as well, while ~98% of PVECs 
were non-BM-derived cells before and after LPS challenge. In addition, it was 
demonstrated that BM-derived cells hardly engrafted as PVECs or proliferated by a BM 
intravenous transfusion experiment and circulating EPCs decreased during the 
reparative phase of PVECs, therefore, we speculated that these are the key reasons 
why circulating EPCs do not significantly participate in the repair of the PVECs. Taken 
together, these results indicate that in the vascular repair phase the main contributing 
PVECs originate from tissue-resident cells and not from circulating EPCs.  
 
In the last decade, there has been a controversy regarding the contribution of BM-
derived circulating cells to the reparative process after pulmonary vascular injury. This 
might be due to differences not only in the adopted methods, but also the objective of 
each study, i.e., the existence and function of BM-derived EPCs or their percentage in 
the whole population of EPCs participating in the repair process. For example, 
Voswinckel et al. (17) revealed using immunohistochemistry that BM-derived cells 
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were hardly involved in regenerative lung growth in mice, and Ohle et al. (18) showed 
using FCM that BM-derived cells did not contribute to maintenance and repair of 
PVECs after hyperoxia-induced endothelial injury. These results were similar to ours. 
On the other hand, Yamada et al. (13) demonstrated using immunohistochemistry 
that BM-derived PVECs participated in the reparative process of LPS-injured lungs and 
emphasized the importance of BM-derived cells, and their findings seems to be 
conflicting with ours. Nevertheless, as shown in Figure 3G, ~5% of proliferating 
PVECs were GFP+ indicating the existence of BM-derived EPCs, as previously 
suggested by Yamada et al (13). 
 
After the existence of circulating non-hematopoietic EPCs was shown (32), the 
existence of vascular wall-resident EPCs from human umbilical vein and aorta with a 
clonal proliferative potential and in vivo vessel-forming capacity (9) and that of 
tissue-resident EPCs from the small intestine and liver that contribute to postnatal 
vasculogenesis (33) have been reported. Thus, the tissue-resident EPCs have been 
thought to be the origin of circulating non-hematopoietic EPCs. Moreover, the 
presence of tissue-resident EPCs has also received attention in the field of pulmonary 
diseases, and it was demonstrated in human and rodents lungs by functional assay of 
single cell suspensions and histological analyses (19-21, 34). Although it has 
remained to be clarified how EPCs contribute to vascular repair of injured local tissue, 
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this study provides reliable evidence tending to solve this issue. 
 
  Regarding the location of tissue-resident EPCs in lungs, a significant proliferative 
response of PVECs was observed in capillary lesions during the reparative phase. 
Although it has been reported that pulmonary microvascular endothelial cells are 
enriched with progenitor cells with vasculogenic capacity (19) and grow 
approximately twice as fast as pulmonary artery endothelial cells (35), the exact 
anatomical location of proliferating PVECs during the regenerative process remains to 
be clarified. Therefore, our finding that should help understand the cellular 
mechanism of the reparative process of lung vessels. 
  
 Our results showing that normally slow cycling PVECs turned to be highly 
proliferative and participated in vascular repair strongly suggested that PVECs include 
functional EPCs. In addition, we demonstrated that nascent PVECs had EPC-capacities 
such as colony and vessel formation and the specialized functions of progenitor cells 
including ROS-scavenging capacity, aldehyde dehydrogenase activity and enhanced 
expression of drug resistance genes.  
 
Several reports have demonstrated that functional activities of EPCs are closely 
related with low levels of intracellular ROS (36-38), therefore the ROS reduction we 
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found in regenerating PVECs suggested that lung tissue-resident EPCs actively 
exerted that function.  
 
High ALDH enzymatic activity is one of the specialized markers not only for various 
types of stem cells, but also for neural, hematopoietic, mammary epithelial and 
pancreatic ductal progenitors (39-41), therefore, our data showing augmented ALDH 
activity of regenerating PVECs was considered to reflect their functional phenotype as 
progenitor cells.  
 
The expression of drug resistance factors, i.e. ATP-binding cassette transporter 
genes, in progenitor cells was reported in diverse types of the cells (10, 42, 43). A 
preceding study on cardiac muscle progenitor cells that were identified by their 
unique ability to exclude Hoechst dye, indicated the importance of excreting 
exogenous substances during tissue reparative process (29). Thus, the increased 
expression of Abcb1b observed after LPS challenge might reflect functional activity of 
regenerating PVECs as progenitor cells.  
 
Although it is indicated that regenerating PVECs include functional EPCs, further 
research is needed to evaluate whether PVECs characterized by Abcb1b gene 
expression, ALDH or ROS scavenging activity display EPC functions more than those 
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showing no expression of the Abcb1b gene, ALDH or ROS scavenging activity and 
these characteristics could be used as a mean to enrich lung tissue-resident EPCs.  
 
In the present study, cell surface markers (CD34, Flk-1/KDR, Prom1/CD133 and c-
kit) of tissue-resident EPCs lacked uniformity on day 7 of LPS challenge. In addition, 
proliferating PVECs expressed CD34, Flk-1/KDR and c-kit more strongly, but 
Prom1/CD133 less than non-proliferating PVECs, suggesting tissue-resident EPCs 
expressed CD34, Flk-1/KDR and c-kit more, but Prom1/CD133 less than the rest of 
PVECs. Although no cell surface markers have been identified to distinguish EPCs from 
the rest of PVECs (31), we could phenotypically discriminate tissue-resident EPCs 
from the rest of PVECs in vivo using FCM in the present study. In prior reports, 
Alvarez et al. (19) showed that rat resident microvascular EPCs proliferating in vitro 
expressed CD34 and Flk-1/VEGFR2, but Prom1/CD133; Schniedermann et al. (20) 
demonstrated that mouse PVECs grown in vitro expressed CD34, Prom1/CD133 and 
Flk-1/VEGFR2, but not c-kit; and Fang et al. (21) revealed that mouse c-kit+PVECs 
exerted functions of vascular endothelial stem cells than c-kit-PVECs. Thus, surface 
markers on EPCs in vitro were shown to be homogeneous in each report but not to be 
fully consistent. However, cell properties in vivo differ from those in vitro and PVECs, 
whether proliferating or non-proliferating, in vivo might be heterogeneous and 
express various surface markers. Thus, in this study we could detect one of the in 
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vivo pathophysiological cell characteristics and the difference between lung tissue-
resident EPCs and the rest of PVECs. PVECs, whether proliferating or non-
proliferating, were mostly Flk-1/KDR negative. A previous study showed that Flk-
1/VEGFR2 protein was not detected in vessels of normal lung, liver, heart, and brain 
cortex, but mRNA for Flk-1/VEGFR2 could be detected in the vascular endothelium, 
and the reason for the negative staining of vessels may be due to differences in the 
sensitivity of protein and mRNA detection techniques, or to rapid turnover of Flk-
1/VEGFR2 protein on vessels (44). Therefore, this could partly explain why most 
PVECs were Flk-1/KDR negative. 
 
There are some questions derived from our findings that need to be answered, 1) 
whether similar results can be shown under other conditions, i.e. in mice of different 
age, in lung injured by insults other than intratracheal LPS challenge or in humans as 
well as in mouse lung; 2) the mechanism how lung tissue-resident EPCs are activated 
and controlled; 3) whether these EPCs grown in vitro could be used in transplant 
therapy. Therefore further research should be needed. 
 
 In conclusion, this study provides important evidence on the endothelial reparative 
process in endotoxin-induced lung injury; namely, that lung tissue-resident EPCs 
rather than circulating EPCs predominantly contribute to pulmonary vascular repair 
27 
 
after endotoxin-induced injury. These findings strengthen our understanding of 
vascular biology in the light of EPCs participation in the pathological mechanism of 
ARDS and could lead to the development of therapeutic strategy for ARDS based on 
the promotion of tissue repair.  
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Figure legends 
Figure 1. Changes in body weight and results of FCM analyses after LPS-challenge. 
(A) Body weight significantly decreased on day 3 and recovered on day 7 (n=18-
124). (B, C) The number of CD31-/CD45+ leucocytes and Gr-1+/CD11b+/CD31-/CD45+ 
neutrophils significantly increased on day 3, and diminished almost reaching the 
baseline value on day 7 (n=5-8). (D) CD31+/CD45- pulmonary vascular endothelial 
cells (PVECs) significantly decreased on days 1 and 3, and almost reach the baseline 
value on day 7 (n=7). (E) Percentage of PVECs unstained by Hoechst dye (apopototic 
PVECs) increased on day 1 and then significantly decreased on day 7. (F) The 
percentage of BrdU+-gated PVECs significantly increased on day 3, 5 and 7 (n=4). (G) 
Representative FCM panels with BrdU+-gated PVECs are shown. (H) Expression of 
Mki67 in PVECs also significantly increased on day 7 (n=3). (A, D) Median values are 
presented (25th-75th interquartile range). (B, C and E-H) Values are means ± SD, *P 
< 0.05, ***P < 0.001.  
 
Figure 2. After LPS challenge, proliferating PVECs located preferentially in capillary 
vessels. Immunofluorescence staining was performed with Hoechst dye (blue), anti-
CD31 (green), -Ki67 (red) and -CD45 (orange) antibodies. (A) Time course 
examination of lung tissue by confocal microscopy showed few proliferating PVECs 
defined as CD31+/Ki67+/CD45- in the non-stimulating state (control), whereas they 
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were noticeable in capillary vessels on days 3, 5 and 7 (arrowheads). Scale bars, 50 
µm. (B) Few proliferating PVECs were detected in non-capillary vessels throughout a 
week. Scale bars, 50 µm. (C) Histological quantification revealed that the number of 
PVECs increased significantly in capillary vessels after LPS-challenge, although no 
significant change was seen in the large and middle (non-capillary) vessels. **P < 
0.01 (n = 3). Values are means ± SD. 
 
Figure 3. Most of new PVECs arose from non-BM derived cells and BM-derived cells 
hardly engrafted as new PVECs. BM-chimera mice reconstituted with GFP-expressing 
BM cells were analyzed by FCM to detect the origin of lung cells. Representative FCM 
panels of GFP+ peripheral blood cells (A), lung interstitial leucocytes (B) and PVECs 
(C) in control lungs are shown. (D) GFP- cells were predominant in PVECs before and 
after LPS challenge (comparison between GFP+ and GFP- cells, n = 3). (E) The 
percentage of GFP+ cells in PVECs remained low and showed only a minor alteration 
throughout 3 weeks (n = 3). (F) The percentage of BrdU+ cells in PVECs was 
significantly increased on day 7 similar to the course observed in the experiments 
with WT mice, and then decreased to reach the baseline on day 21 (n = 3). (G) The 
percentage of GFP+ cells among BrdU+PVECs decreased gradually during 3 weeks 
after LPS challenge (n = 3). (H, I) Mice repeatedly transfused with GFP-expressing 
BM cells were analyzed. (H) The number of GFP+ lung interstitial leukocytes increased 
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on day 7 of LPS challenge compared to the control (without LPS challenge) and 
decreased on from day 7 to day 21 (n = 4). (I) In contrast, the number of GFP+PVECs 
showed only a minor alteration. The number of GFP+ among LPS-PVECs decreased 
slightly on days 7 and 21 compared to each controls, and decreased from on day 7 to 
day 21 (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001. Not significant; N.S., Values 
are means ± SD.  
 
Figure 4. LPS challenge led to a decrease in the number of circulating phenotypical 
EPCs. The dynamics of circulating phenotypical EPCs, and CD31+/CD45- cells which 
might include tissue-resident EPCs from other organs after LPS challenge were 
evaluated by FCM. (A, B) The number of circulating EPCs defined as Flk-1/KDR and 
CD133/Prom1, or Flk-1/KDR and CD34 double-positive cells in peripheral blood were 
examined. There was a significant decrease in the number of circulating EPCs on day 
1, followed by gradual increase, but without reaching the basal level during 7 days 
(n=6). Median values are presented (25th-75th interquartile range). (C) The number 
of circulating CD31+/CD45- cells, which might include tissue-resident EPCs, in 
peripheral blood increased slightly on day 1, but decreased to baseline or below it on 
days 3-7 (n = 3). *P < 0.05, **P < 0.01. Not significant; N.S., Values are means ± 
SD.  
 
39 
 
Figure 5. PVECs were shown to include EPCs with colony-forming and vasculogenic 
capacities that were activated by LPS challenge. PVECs isolated from lungs of control 
mice (control-PVECs) and of mice on day 5 after LPS-challenge (LPS-PVECs) were 
cultured on gelatinized plates. Each group of PVECs was isolated from five mice and 
1.0×106 cells/well were seeded. (A) Representative cell colonies (consisting of more 
than 30 cells) on day 12 of culture are shown. Scale bars, 250 µm. (B) The number of 
colonies derived from LPS-PVECs was significantly higher than that of colonies derived 
from Normal-PVECs. The number of colonies was determined by counting five wells. 
Values are means ± SD, ***P < 0.001. (C) Vasculogenesis assay was performed on 
MatrigelTM-coated slide chambers. Control-PVECs exhibited sphere-like colony 
formation and very short tube structure on day 15 and remained unchanged until day 
28. (D) In contrast, LPS-PVECs showed not only sphere-like colonies but obvious net-
like tube formation on day 12 and expansion of the tube structure on day15. (E) As 
controls of tube formation, primary CD31+/CD45- endothelial cells isolated from heart 
and aorta were used and in both cases these cells showed sphere-like colony 
formation surrounded by a tube-like structure on days 11 and 18, similar to PVECs. 
Scale bars, 250 µm. (F, G) LPS-PVECs from GFP-Tg mice (passage 6) mixed with 
Matrigel and growth factors were injected into the back of WT mice. (F) After 10 days, 
the plugs were harvested and vessel structures were noted (arrowhead). Scale bars, 
10 mm. (G) Confocal microscopy analysis of the plugs immunostained by combination 
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with Hoechst dye, anti-CD31 and -GFP antibodies demonstrated CD31+/GFP+ injected 
cells (arrowhead) were engrafted in CD31+/GFP- host vessels. Scale bars, 50 µm. 
 
Figure 6. Regenerating PVECs showed capacity for reducing oxidative stress, 
augmented ALDH activity and upregulation of Abcb1b gene expression, suggesting 
activation of tissue-resident EPC functions. (A) Fluorescence intensity of oxidized 
DCF-DA was measured to evaluate intracellular oxidative stress by FCM analysis. The 
relative values of mean fluorescence intensities of viable PVECs (PI-/CD31+/CD45- 
cells) from control- and LPS-PVECs are shown. The intensity increased within a day 
and then significantly decreased until day 7 of LPS challenge. *P < 0.05 (n = 3). (B) 
Time course changes in gene expression related to ROS-scavenging in LPS-PVECs 
compared with those in control-PVECs. The expression of Cat1, Gpx1 and Sod2 was 
slightly enhanced after LPS challenge (n = 3). (B) The percentage of viable PVECs (PI-
/CD31+/CD45- cells) that expressed ALDH activity was measured by FCM analysis. 
About 3 % of PVECs was shown to exhibit ALDH activity in the non-stimulating state 
and the proportion of these cells increased slightly after LPS challenge (n = 2). (D) 
Time course changes in the expression of genes related to ALDH activity. The 
expression of Aldh1b1 and Aldh2 was slightly enhanced after LPS challenge (n = 3). 
(E) Similarly, time course qPCR analysis of isolated primary PVECs was performed to 
evaluate drug resistance gene expression. As a result, Abcb1b, an ATP-binding 
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cassette transporter, drug resistance gene, was significantly upregulated on day 1. 
***P < 0.001 (n = 3). Not significant; N.S., Values are means ± SD. 
 
Figure 7. Regenerating PVECs showed enhanced gene expression of CD34 and 
expressed CD34, Flk-1/KDR and c-kit on the cell surface more strongly than non-
proliferating PVECs. (A) Time course qPCR analysis of isolated primary PVECs was 
performed to evaluate the expression of putative EPC markers. As a result, Cd34 was 
significantly upregulated after LPS challenge. *P < 0.05 (n = 3). (B) Phenotype of 
putative EPC markers was compared by FCM between non-proliferating (BrdU-) and 
proliferating (BrdU+) PVECs of day 7 after LPS challenge. As a result, the percentages 
of cells positive for CD34, Flk-1/KDR and c-kit were higher in BrdU+PVECs and those 
of cells positive for Prom1/CD133 were lower in BrdU+PVECs. *P < 0.05, **P < 0.01 
(n = 3). Values are means ± SD. 
  
42 
 
Vascular repair by tissue-resident endothelial progenitor cells in endotoxin-
induced lung injury 
Takeshi Kawasaki, Ayumi Sekine, Rintaro Nishimura, Rika Suda, Takashi Urushibara, 
Toshio Suzuki, Shin Takayanagi, Jiro Terada, Seiichiro Sakao and Koichiro Tatsumi 
 
Online Data Supplement  
 
43 
 
Materials and Methods 
Animal care and preparation of the endotoxin-induced lung injury model 
All mice had free access to food and water. At baseline, mice were weighed and 
anesthetized by intraperitoneal injection of pentobarbital before tracheal exposure or 
harvest. Seven- to eight-week-old female C57BL/6 mice (Clea Japan, Tokyo, Japan) 
were intratracheally administered 100 µg LPS from Escherichia coli (O55:B5 Sigma, 
St Louis, MO) dissolved in 100 µl of phosphate buffered saline (PBS) using a 29-
gauge needle. At specified time points after the instillation, the mice were 
anesthetized and killed by exsanguination from the inferior vena cava. All animal 
experiments were conducted under protocols approved by the Review Board for 
animal experiments of Chiba University.  
 
Bromodeoxyuridine labeling for detection of proliferating cells 
For in vivo bromodeoxyuridine (BrdU; Sigma) labeling, the mice were injected 1 mg 
BrdU in 200 µl PBS intraperitoneally 12 and 24 hours before sacrifice and were 
provided drinking water containing 0.8 mg/ml of BrdU for 24 hours. 
 
Lung single cell suspension 
At the time of harvest, the lungs were perfused blood free with 30 ml PBS containing 
10 U/ml heparin (Novo- Heparin, Mochida, Tokyo) from the right ventricle, then 
minced and digested in an enzyme cocktail of DMEM (Sigma) containing 1% of bovine 
serum albumin (BSA; Wako, Osaka, Japan), 2 mg/ml of collagenase (Wako), 100 
µg/ml of DNase (Wako), and 2.5 mg of Dispase II (Roche Diagnostics GmbH, 
Mannheim, Germany) at 37 °C for 60 minutes, then meshed through a 100 µm nylon 
cell strainer. 
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Flow cytometry analysis of lung cells 
Lung cells were pretreated with anti-CD16/32 antibody (Ab) (BioLegend, San Diego, 
CA) to block Fc receptors, and then incubated with specific antibodies (Abs) in the 
dark at 4 °C. The following Abs were used for cell surface staining: endothelial cells 
were identified with anti-CD31-PE/Cy7 (BioLegend), hematopoietic cells with anti-
CD45-Alexa700 (BioLegend), neutrophils with anti-CD11b-FITC (BioLegend) and anti-
Ly-6G/Ly-6C (Gr-1) -Alexa647 (BioLegend), anti-Flk-1/KDR-PE (eBioscience, San 
Diego), biotinylated anti-CD34 (BioLegend), biotinylated anti-CD133 (eBioscience), 
anti-CD117/c-kit-PE (BioLegend) and streptavidin-PE Abs (BioLegend). For 
measurement of DNA degradation, the cells were also incubated with 10 µg/ml of 
Hoechst 34580 (Life Technologies, Grand Island, NY) for 30 minutes in the dark at 
37 °C. For detecting proliferating cells, BrdU APC flow kit (BD Pharmingen, San Diego) 
was used for staining intracellular BrdU according to the manufacturer’s protocol. 
Mouse IgG-APC (BioLegend) was used as an isotype control. For measurement of 
intracellular reactive oxygen species (ROS), after surface staining the cells were 
incubated with 20 µM of dichlorofluorescein diacetate (DCF-DA; Life Technologies) for 
30 minutes in the dark at 37 °C. To assay cellular aldehyde dehydrogenase (ALDH) 
activity, ALDEFLUORTM kit (STEMCELL Technologies, Vancouver, BC, Canada) was used 
according to the manufacturer’s protocol. Propidium iodide (Sigma) at a concentration 
of 0.5 µg/ml was used to evaluate the cell viability. Cell fluorescence was measured 
using FACSCantoTM II instrument (Becton Dickinson, San Jose, CA) and analyzed 
employing FlowJo software (Tree Star, San Carlos, CA).  
 
Confocal microscopy analysis of lung tissue 
45 
 
Lungs were embedded in OCT (SAKURA Finetek, Tokyo) and frozen in liquid nitrogen 
to prepare the cryosections. Frozen lung tissues were cut into 6-µm-thick sections, 
immunostained and visualized by confocal microscopy (Fluoview FV 10i, Olympus, 
Tokyo). The sections were fixed in acetone for 10 minutes, blocked by Block Ace 
(Dainippon Sumitomo Pharma, Tokyo) for 10 minutes, and incubated with the primary 
and secondary Abs for 60-120 minutes. The following Abs were used for triple 
immunostaining: first, rat anti-CD31- Alexa488 (BioLegend) as primary Ab and anti-
rat IgG-Alexa488 (BioLegend) as secondary Ab were used to identify PVECs. Rat 
IgG2a-Alexa488 (BioLegend) was used as an isotype control of the primary Ab. 
Second, rabbit anti-Ki67 (Abcam, Cambridge, MA, UK) as primary Ab and donkey 
anti-rabbit IgG-Alexa 555 (Life Technologies) as secondary Ab were used to identify 
proliferating cells. Rabbit IgG was used as an isotype control of the primary Ab. 
Finally, rat anti-CD45-Alexa647 (BioLegend) and Hoechst 34580 (Sigma) were used 
simultaneously to identify the hematopoietic cells and counterstain cell nuclei. Rat 
IgG2b-Alexa647 (BioLegend) was used as an isotype control of the former. 
 
Histological quantification 
To determine the location of proliferating PVECs, we separated vessels into three 
groups by diameter and morphology: 100 µm or more as “large”, 5 to 100 µm as 
“middle”, and less than 5 µm and flattened shape as “capillary” vessels. The number 
of Ki67+ proliferating PVECs per 100 PVECs was compared between the sections from 
control and LPS challenged (day 5) lungs. 
 
BM reconstitution 
Donor BM cells were obtained from the femoral and peroneal bones of transgenic (Tg) 
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mice that expressed enhanced green fluorescent protein (GFP) under control of CAG 
promoter (GFP-Tg mice; Japan SLC, Shizuoka, Japan). On the same day, recipient wild 
type mice (5weeks old) were irradiated with 5 and 4.5 Gy with an interval of 3 hours 
and transplanted by injection of the donor BM cells (1.0 × 107 cells in 200 µl PBS) 
through the tail vein. 
 
Evaluation of dynamics of circulating phenotypical EPCs 
Mouse blood (200-400 µl) was withdrawn from the inferior vena cava and mixed with 
100 U of heparin (Mochida), and then red blood cells were lysed by adding 0.2 % 
saline. The remaining cells were incubated first with anti-CD16/32 Ab (BioLegend) 
and then stained with specific Abs. The following Abs were used: anti-CD309 
(KDR/Flk-1) -PE (eBioscience), anti-CD34-eFluor660 (eBioscience), biotinylated anti-
CD133 (eBioscience), anti-CD31-PE/Cy7 (BioLegend), and anti-CD45-Alexa700 
(BioLegend) as primary Abs and streptavidin-APC (BioLegend) as secondary Ab. Rat-
IgG2a-PE, Rat-IgG2b-eFluor660 and biotinylated Rat-IgG1 Abs were used as isotype 
controls. 
 
Isolation of mouse PVECs by the magneto-beads method 
Mouse PVECs were defined as CD31+/CD45- cells. Lung cells were incubated with anti-
CD16/32 Ab (BioLegend), and then incubated with anti-CD31-FITC (BioLegend) and 
anti-CD45-PE (BioLegend). For sorting CD31+/CD45- cells, the cells were incubated 
with anti-PE microbeads (Miltenyi Biotec, Auburn, CA) for 15 minutes in the dark at 
4 °C and CD45+ cells were depleted through once in deplete mode of autoMACSTM or 
autoMACSTM Pro Separator (Miltenyi Biotec, Auburn, CA), then the remaining cells 
were incubated with anti-FITC microbeads (Miltenyi Biotec) for 15 minutes in the dark 
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at 4 °C and CD31+ cells were sorted through twice in positive selection mode. 
In vitro proliferation assay of mouse PVECs 
To study the proliferation capacity of mouse PVECs, those isolated (1.0 × 106 cells) 
from the lungs of control (n = 5) or day 5 of LPS challenge (n=5) were seeded in 
DMEM (Wako) supplemented with 10% heat inactivated fetal bovine serum (Wako), 
1mM 4-(2-hydroxyethyl)-1-piperazine ethanesulphonic acid (Life Technologies), 
endothelial cell growth supplement (Sigma), Primocin (InvivoGen, San Diego, CA) and 
12 U/ml heparin (Mochida) on gelatinized 6-well plates (Gelatin Cellware 6-Well Plate; 
Becton Dickinson Labware, UK). After 24 hours, non-adherent cells and debris were 
removed and new medium was applied. The medium was exchanged every other day. 
After 12 days of seeding, the number of colonies, which were defined as clusters of 
30 or more cells, was counted.  
 
In vitro vasculogenesis assay 
To study the vasculogenic capacity of PVECs in vitro, those isolated (4.0 × 105 cells) 
from lung tissue (control and 5 days after LPS challenge) were cultured on MatrigelTM-
coated plates (Chamber Slide, Lab-Tek, Thermo Scientific, USA) in endothelial cell 
basal medium-2 (EBM-2; Lonza, Walkersville, MD) supplemented with EGM-2 MV 
single aliquots (Lonza) consisting of 10% fetal bovine serum, and observed over 28 
days. The medium was exchanged every other day. 
 
In vivo vasculogenesis assay 
PVECs were isolated from GFP-Tg mice of day 5 of LPS challenge (GFP-PVECs), and 
then expanded. The GFP-PVECs (passage 6) mixed with 400 µl of MatrigelTM 
supplemented with VEGF (500 ng/ml; Life Technologies) and bFGF (500 ng/ml; Life 
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Technologies) were injected subcutaneously into the dorsal region of WT mice. After 
10 days, the plugs were harvested, embedded in OCT (SAKURA Finetek) and frozen in 
liquid nitrogen to prepare the cryosections. The plugs were cut into 10-µm-thick 
sections. The sections were fixed in acetone for 60 minutes, blocked by Block Ace 
(Dainippon Sumitomo Pharma, Tokyo) for 10 minutes, and incubated 60 minutes with 
the primary and secondary Abs. The following Abs were used for triple 
immunostaining: first, rat anti-CD31- Alexa488 (BioLegend) as primary Ab and anti-
rat IgG-Alexa488 (BioLegend) as secondary Ab were used to identify PVECs. Rat 
IgG2a-Alexa488 (BioLegend) was used as an isotype control of the primary Ab. 
Second, rabbit anti-GFP-Alexa 555 (Life Technologies) as primary Ab was used to 
identify transplant cells. Finally, Hoechst 34580 (Sigma) was used to counterstain cell 
nuclei. After immunostaining the slides were visualized by confocal microscopy 
(Fluoview FV 10i) 
 
Quantitative polymerase chain reaction analysis  
Total RNA from CD31+/CD45- cells was isolated with Nucleo Spin RNA XS (MACHEREY-
NAGEL GmbH & Co. KG, Diiren, Germany) according to the manufacturer’s 
instructions. The RNA was subjected to reverse transcription polymerase chain 
reaction (RT- PCR) with SuperScript VILO (Life Technologies) according to the 
manufacturer’s protocol and single stranded cDNA was synthesized. The resultant 
cDNA samples were subjected to PCR for amplification using an ABI Prism 7300 
Sequence Detection System (Applied Biosystems, Carlsbad, CA). The specific primers 
and probes were designed using the web software of Universal ProbeLibrary Assay 
Design Center (Roche Applied Science). The Ct value of each sample was normalized 
with Hprt1 as the endogenous control gene and the relative gene expression level was 
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calculated using the 2-ΔΔCt method. Because an appropriate internal control gene 
needs to be used (1), the following 16 candidates were screened; Actb, Gapdh, Gusb, 
Rn18s, Rplp0, Tbp, Atp5f1, Hprt1, Pgk1, Ppia, Rps18, Tfrc, Ywhaz, Oaz1, Rpl13a, and 
Rpl4. Among the genes evaluated, Hprt1 was selected as the suitable internal control 
because its range of gene expression alteration in normal and LPS-PVECs was the 
smallest. Gene symbol and the full name are listed in Table E1. 
 
Statistical analysis 
Values are shown as mean ± SD or median (25–75th percentile). Comparisons were 
performed using Student’s t test, one-way ANOVA or Kruskal-Wallis test followed by 
Tukey’s or Dunn’s multiple comparison as post hoc test. P<0.05 was considered 
statistically significant using GraphPad PRISM software (Version 6.03; GraphPad 
Software, San Diego). 
 
Supplementary references 
E1. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, 
Speleman F. Accurate normalization of real-time quantitative RT-PCR data by 
geometric averaging of multiple internal control genes. Genome biology 2002; 3: 
RESEARCH0034. 
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Table E1. Gene official symbol and the full name 
Official symbol Full name 
Actb  actin beta 
Gapdh  glyceraldehyde-3-phosphate dehydrogenase 
Gusb  glucuronidase, beta 
Rn18s  18S ribosomal RNA 
Rplp0  ribosomal protein, large, P0 
Tbp  TATA box binding protein 
Atp5f1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit B1 
Hprt1  hypoxanthine guanine phosphoribosyl transferase 
Pgk1  phosphoglycerate kinase 1 
Ppia  peptidylprolyl isomerase A 
Rps18  ribosomal protein S18 
Tfrc  transferrin receptor 
Ywhaz tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, zeta polypeptide 
Oaz1  ornithine decarboxylase antizyme 1 
Rpl13a ribosomal protein L13A  
Rpl4  ribosomal protein L4  
Mki67  antigen identified by monoclonal antibody Ki 67 
Kdr  kinase insert domain protein receptor 
Cd34  CD34 antigen 
Prom1  prominin1 
Kit  kit oncogene 
Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1A 
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Abcb1b ATP-binding cassette, sub-family B, member 1B 
Abcg1  ATP-binding cassette, sub-family G (WHITE), member 1 
Abcg2  ATP-binding cassette, sub-family G, member 2 
Gpx1  glutathione peroxidase 1 
Gpx2  glutathione peroxidase 2 
Cat  catalase 
Sod1  superoxide dismutase 1, soluble 
Sod2  superoxide dismutase 2, mitochondrial 
Sod3  superoxide dismutase 3, extracellular 
Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 
Aldh1b1 aldehyde dehydrogenase 1 family, member B1 
Aldh2  aldehyde dehydrogenase 2, mitochondrial 
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Figure legends 
Figure E1.  
Representative panels of FCM analyses related to Figure 1. (A) Hematopoietic cells 
(Leukocytes) defined as CD31-/CD45+ cells and PVECs defined as CD31+/CD45- cells. 
(B) Neutrophils defined as Gr-1+/CD11b+/ CD31-/CD45+ cells. (C) PVECs not stained 
by Hoechst dye were considered to harbor fragmented DNA; that is, they were 
apoptotic PVECs. (D) Cells purity after magneto-beads method for isolation of PVECs.  
 
Figure E2.  
Representative panels of time course FCM analyses related to Figure 3D-G. (A) GFP+ 
cells in PVECs, (B) BrdU+ cells in PVECs and (C) GFP+ cells in BrdU+PVECs were gated 
and the percentages are displayed.  
 
Figure E3. 
Representative panels of FCM analyses related to Figure 3H, I. (A) GFP+ cells in 
leukocytes and (B) GFP+ cells in PVECs were gated and the percentages are 
displayed.   
 
Figure E4. 
Representative panels of time course FCM analyses related to Figure 4A-C. (A) Flk-
1/KDR and CD133/Prom1 cells, (B) Flk-1/KDR and CD34 cells, and (C) CD31 and 
CD45 cells in peripheral blood cells were gated and the percentages are displayed. 
 
Figure E5. 
Representative panels of time course FCM analyses related to Figure 6A. The cells 
53 
 
with fluorescence intensity indicating oxidized DCF-DA were counted. 
 
Figure E6 
Representative panels of time course FCM analyses related to Figure 6C. ALDH+PVECs 
were gated and the percentages are displayed. The lower panels shows the negative 
control of each group using diethylaminobenzaldehide (DEAB), a specific ALDH 
inhibitor.  
 
Figure E7 
Representative panels of time course FCM analyses related to Figure 7B. CD34+, Flk-
1/KDR+, Prom1/CD133+ and c-kit+ in BrdU- or BrdU+PVECs were gated and the 
percentages are 
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